Arthur Shen

TL;DR: In this article, the authors conducted an analysis of the safety and pharmacokinetics of direct intrathecal administration of rituximab using cynomolgus monkeys and found that drug clearance from the CSF is biphasic, with a terminal half-life of 4.96 hours.

TL;DR: In this article, the authors conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).

TL;DR: It is demonstrated that interleukin-4 (IL-4) is expressed by tumor vasculature as well as by tumor cells in CNS lymphomas, and high expression of activated STAT6 in tumors was associated with short survival in an independent set of patients with primary CNS lymphoma who were treated with high-dose intravenous methotrexate therapy.

TL;DR: To the editor: While primary central nervous system lymphoma (PCNSL) may be classified among the 3 established molecular subclasses of large B- cell lymphoma: germinal center, activated B-cell, and type 3 based upon gene expression profiles, 2 recent microarray-based expression profiling

TL;DR: An analysis of the safety and pharmacokinetics of intrathecal Rituximab administration in nonhuman primates is conducted and these results constitute the basis for the current phase I study of intraventricular RitUXIMab administration.